DDInter1492 DDInter1676
Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Ponatinib {u} (Compound) binds {v} (Gene) RET
Ponatinib {u} (Compound) upregulates {v} (Gene) RAB15
Ponatinib {u} (Compound) downregulates {v} (Gene) ATP6V0B
Ponatinib {u} (Compound) causes {v} (Side Effect) Migraine
Ponatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ranitidine
Ponatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sodium citrate
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vibrio cholerae CVD 103-HgR strain live antigen
Ponatinib {u} may lead to a major life threatening interaction when taken with {v} Ramucirumab
Ponatinib {u} may lead to a major life threatening interaction when taken with {v} Tucatinib
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Ponatinib (Compound) binds RET (Gene)
Ponatinib (Compound) upregulates RAB15 (Gene)
Ponatinib (Compound) downregulates ATP6V0B (Gene)
Ponatinib (Compound) causes Migraine (Side Effect)
Ponatinib may cause a minor interaction that can limit clinical effects when taken with Ranitidine
Ponatinib may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Ponatinib may lead to a major life threatening interaction when taken with Ramucirumab
Ponatinib may lead to a major life threatening interaction when taken with Tucatinib